Pharmacogenomic biomarkers: New tools in current and future drug therapy

Trends in Pharmacological Sciences

Volumn 32, Issue 2, 2011, Pages 72-81

  Sim, Sarah C ^a   Ingelman Sundberg, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALLOPURINOL; AMOXICILLIN PLUS CLAVULANIC ACID; AROMATASE INHIBITOR; AZATHIOPRINE; BIOLOGICAL MARKER; CARBAMAZEPINE; CETUXIMAB; CLOPIDOGREL; CODEINE; ERLOTINIB; FLUCLOXACILLIN; GEFITINIB; IMATINIB; IRINOTECAN; MARAVIROC; MERCAPTOPURINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PANITUMUMAB; PEGINTERFERON ALPHA; PLACEBO; PLATINUM; RIBAVIRIN; SIMVASTATIN; TAMOXIFEN; TRASTUZUMAB; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; WARFARIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE LYMPHOBLASTIC LEUKEMIA; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BLEEDING; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER RELAPSE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DEPRESSION; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DEPRESSION; DRUG BLOOD LEVEL; DRUG HYPERSENSITIVITY; DRUG METABOLISM; ENTERITIS; EPILEPSY; EVENT FREE SURVIVAL; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TOXICITY; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GRAFT REJECTION; HEPATITIS C; HER1 GENE; HER2 GENE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERURICEMIA; IL28B GENE; LEUKEMIA; LUNG NON SMALL CELL CANCER; MYOPATHY; NEUTROPENIA; ONCOGENE C KIT; ONCOGENE K RAS; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHARMACODYNAMICS; PHARMACOGENOMICS; PRIORITY JOURNAL; RESPIRATION DEPRESSION; REVIEW; SIDE EFFECT; SLC6A4 GENE; STAPHYLOCOCCUS INFECTION; STENT THROMBOSIS; STEVENS JOHNSON SYNDROME; STOMACH CANCER; SUICIDE; SYSTEMIC MASTOCYTOSIS; THROMBOSIS; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS; VIRAL TROPISM;

BIOMARKERS, PHARMACOLOGICAL; DRUG MONITORING; HUMANS; PHARMACOGENETICS;

EID: 79651470986     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2010.11.008     Document Type: Review

References (70)

1. M. Pirmohamed Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients Br. Med. J. 329 2004 15 19 (Pubitemid 38869995)
2. E.C. Davies Emergency re-admissions to hospital due to adverse drug reactions within 1 year of the index admission Br. J. Clin. Pharmacol. 70 2010 749 755
3. D.B. Jefferys New active substances authorized in the United Kingdom between 1972 and 1994 Br. J. Clin. Pharmacol. 45 1998 151 156 (Pubitemid 28045682)
4. M. Eichelbaum Pharmacogenomics and individualized drug therapy Annu. Rev. Med. 57 2006 119 137 (Pubitemid 43261982)
5. E.C. Davies Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient episodes PLoS One 4 2009 e4439
6. W. Schroth Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen J. Am. Med. Assoc. 302 2009 1429 1436
7. C. Rodriguez-Antona Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment Hum. Genet. 127 2010 1 17
8. M.J. Higgins, and V. Stearns CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance Curr. Oncol. Rep. 12 2010 7 15
9. J.M. Hoskins CYP2D6 and tamoxifen: DNA matters in breast cancer Nat. Rev. Cancer 9 2009 576 586
10. W. Schroth Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes J. Clin. Oncol. 25 2007 5187 5193 (Pubitemid 350232249)
11. S. Marsh, and J.M. Hoskins Irinotecan pharmacogenomics Pharmacogenomics 11 2010 1003 1010
12. C. Schulz UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy? Anticancer Drugs 20 2009 867 879
13. N. Karas-Kuzelicki, and I. Mlinaric-Rascan Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond Pharmacogenomics 10 2009 1309 1322
14. J.E. Higgs Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics 11 2010 177 188
15. L.R. Trevino Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects J. Clin. Oncol. 27 2009 5972 5978
16. C.L. Corless Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816 V and D816F mutations in mastocytosis and acute myelogenous leukemia J. Mol. Diagn. 8 2006 604 612 (Pubitemid 44774160)
17. H.R. Chang Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer Cancer 116 2010 2856 2867
18. R.G. Amado Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J. Clin. Oncol. 26 2008 1626 1634
19. J.R. Hecht Lack of correlation between epidermal growth factor receptor status and response to panitumumab monotherapy in metastatic colorectal cancer Clin. Cancer Res. 16 2010 2205 2213
20. A. Lievre KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res. 66 2006 3992 3995
21. T.S. Mok Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N. Engl. J. Med. 361 2009 947 957
22. T. Yoshida Targeting epidermal growth factor receptor: central signaling kinase in lung cancer Biochem. Pharmacol. 80 2010 613 623
23. I. Johansson Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine Proc. Natl. Acad. Sci. U. S. A. 90 1993 11825 11829 (Pubitemid 24008732)
24. V. Rollason Pharmacogenetics of analgesics: toward the individualization of prescription Pharmacogenomics 9 2008 905 933
25. J.A. Agundez Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin. Drug Metab. Toxicol. 5 2009 607 620
26. U.M. Stamer Personalized therapy in pain management: where do we stand? Pharmacogenomics 11 2010 843 864
27. G. Koren Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother Lancet 368 2006 704 (Pubitemid 44223697)
28. C.M. Perry Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection Drugs 70 2010 1189 1213
29. A.K. Daly HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin Nat. Genet. 41 2009 816 819
30. A.K. Daly, and C.P. Day Genetic association studies in drug-induced liver injury Semin. Liver Dis. 29 2009 400 411
31. P.T. Donaldson Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury J. Hepatol. 53 2010 1049 1053
32. G. Ahlenstiel IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice J. Gastroenterol. 45 2010 903 910
33. D. Ge Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
34. D.L. Thomas Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 2009 798 801
35. S. Mallal HLA-B*5701 screening for hypersensitivity to abacavir N. Engl. J. Med. 358 2008 568 579
36. M. Ingelman-Sundberg Pharmacogenomic biomarkers for prediction of severe adverse drug reactions N. Engl. J. Med. 358 2008 637 639 (Pubitemid 351214293)
37. T.L. Kauf Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV Pharmacoeconomics 28 2010 1025 1039
38. M. Ingelman-Sundberg Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects Pharmacol. Ther. 116 2007 496 526 (Pubitemid 350116943)
39. A.L. Zackrisson High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases Clin. Pharmacol. Ther. 88 2010 354 359
40. D.L. Murphy Serotonin transporter: gene, genetic disorders, and pharmacogenetics Mol. Interv. 4 2004 109 123 (Pubitemid 38584973)
41. A. Serretti Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients Mol. Psychiatry 12 2007 247 257 (Pubitemid 46328503)
42. M.J. Taylor Antidepressant response and the serotonin transporter gene-linked polymorphic region Biol. Psychiatry 68 2010 536 543
43. D. Franciotta Genetic basis for idiosyncratic reactions to antiepileptic drugs Curr. Opin. Neurol. 22 2009 144 149
44. J.S. Hulot Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2006 2244 2247
45. M. Kazui Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite Drug Metab. Dispos. 38 2010 92 99
46. J.L. Mega Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis J. Am. Med. Assoc. 304 2010 1821 1830
47. G. Paré Effects of CYP2C19 genotype on outcomes of clopidogrel treatment N. Engl. J. Med. 363 2010 1704 1714
48. L. Wallentin Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial Lancet 376 2010 1320 1328
49. A.M. Harmsze CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study Eur. Heart J. 2010 DOI: 10.1093/eurheartj/ehq321
50. K.A. Tiroch Protective effect of the CYP2C19*17 polymorphism with increased activation of clopidogrel on cardiovascular events Am. Heart J. 160 2010 506 512
51. D. Sibbing Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement Circulation 121 2010 512 518
52. D.E. Jonas, and H.L. McLeod Genetic and clinical factors relating to warfarin dosing Trends Pharmacol. Sci. 30 2009 375 386
53. P. Lenzini Integration of genetic, clinical, and INR data to refine warfarin dosing Clin. Pharmacol. Ther. 87 2010 572 578
54. N.A. Limdi Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups Blood 115 2010 3827 3834
55. M. Teichert A genome-wide association study of acenocoumarol maintenance dosage Hum. Mol. Genet. 18 2009 3758 3768
56. E. Link SLCO1B1 variants and statin-induced myopathy - a genomewide study N. Engl. J. Med. 359 2008 789 799
57. A. Kalliokoski, and M. Niemi Impact of OATP transporters on pharmacokinetics Br. J. Pharmacol. 158 2009 693 705
58. M. Lissia Toxic epidermal necrolysis (Lyell's disease) Burns 36 2010 152 163
59. S.I. Hung HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol Proc. Natl. Acad. Sci. U. S. A. 102 2005 4134 4139
60. W. Tassaneeyakul Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population Pharmacogenet. Genomic 19 2009 704 709
61. N. Kaniwa HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis Pharmacogenomics 9 2008 1617 1622
62. C. Lonjou A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs Pharmacogenet. Genomics 18 2008 99 107
63. R.R. Shah Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics 7 2006 889 908 (Pubitemid 44446737)
64. J.B. Singer A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury Nat. Genet. 42 2010 711 714
65. F.W. Frueh Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: prevalence of related drug use Pharmacotherapy 28 2008 992 998
66. M.V. Relling Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism Lancet Oncol. 11 2010 507 509
67. Nature News Human genome at ten: the sequence explosion Nature 464 2010 670 671
68. E.A. Ashley Clinical assessment incorporating a personal genome Lancet 375 2010 1525 1535
69. D. Sibbing Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy J. Thromb. Haemost. 8 2010 1635 1693
70. D. Sibbing Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention Eur. Heart J. 30 2009 916 922